Apheresis in Neurological Disorders
Dorst, Johannes
Apheresis in Neurological Disorders - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020 - 1 electronic resource (174 p.)
Open Access
Apheresis refers to an extracorporeal therapy which aims at removing pathological constituents from the patients’ blood. Due to the development of new techniques as well as the discovery of novel autoimmune antibodies, it is increasingly recognized as an important therapeutic option for a variety of autoimmune-mediated neurological disorders, including multiple sclerosis, myasthenia gravis, autoimmune encephalitis, Guillain–Barré syndrome, and many others. Therapeutic plasma exchange (TPE) constitutes the standard method of apheresis for most indications, while immunoadsorption (IA) offers a more specific, low-risk alternative. Both methods aim at removing auto-antibodies from the blood. Evidence for most neurological diseases is still low. Interestingly, more recent developments suggest that apheresis is not limited to the removal of autoantibodies but may also be useful in neurodegenerative and possibly even in acute vascular disorders.
Creative Commons
English
books978-3-03943-586-9 9783039435852 9783039435869
10.3390/books978-3-03943-586-9 doi
Medicine
immunoadsorption acute relapsing multiple sclerosis plasma exchange therapeutic apheresis multiple sclerosis optic neuritis relapse class IV steroids Alzheimer’s clinical syndrome dementia autoantibodies α1-Adrenergic receptor Inflammatory neuropathy chronic inflammatory demyelinating polyneuropathy Guillain-Barré syndrome paranodal antibodies plasmapheresis Myalgic Encephalomyelitis/Chronic Fatigue Syndrome ß2 adrenoreceptor autoantibody autoimmune encephalitis limbic encephalitis NMDAR (N-Methyl-D-Aspartat) antibody paraneoplastic apheresis therapeutic plasma exchange neurological diseases CRP stroke inflammation n/a
Apheresis in Neurological Disorders - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020 - 1 electronic resource (174 p.)
Open Access
Apheresis refers to an extracorporeal therapy which aims at removing pathological constituents from the patients’ blood. Due to the development of new techniques as well as the discovery of novel autoimmune antibodies, it is increasingly recognized as an important therapeutic option for a variety of autoimmune-mediated neurological disorders, including multiple sclerosis, myasthenia gravis, autoimmune encephalitis, Guillain–Barré syndrome, and many others. Therapeutic plasma exchange (TPE) constitutes the standard method of apheresis for most indications, while immunoadsorption (IA) offers a more specific, low-risk alternative. Both methods aim at removing auto-antibodies from the blood. Evidence for most neurological diseases is still low. Interestingly, more recent developments suggest that apheresis is not limited to the removal of autoantibodies but may also be useful in neurodegenerative and possibly even in acute vascular disorders.
Creative Commons
English
books978-3-03943-586-9 9783039435852 9783039435869
10.3390/books978-3-03943-586-9 doi
Medicine
immunoadsorption acute relapsing multiple sclerosis plasma exchange therapeutic apheresis multiple sclerosis optic neuritis relapse class IV steroids Alzheimer’s clinical syndrome dementia autoantibodies α1-Adrenergic receptor Inflammatory neuropathy chronic inflammatory demyelinating polyneuropathy Guillain-Barré syndrome paranodal antibodies plasmapheresis Myalgic Encephalomyelitis/Chronic Fatigue Syndrome ß2 adrenoreceptor autoantibody autoimmune encephalitis limbic encephalitis NMDAR (N-Methyl-D-Aspartat) antibody paraneoplastic apheresis therapeutic plasma exchange neurological diseases CRP stroke inflammation n/a